Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks like another FITX.A shell company designed to use shareholders to build a facility.
I see the same thing happening with my account.Constantly jumping up or down $100 at a time and slowly taking every penny.I won't sell now in case of a class action litigation against FITX.There are all kinds of pictures and proof that they were incompetent.They had the facility built only to lose on a "technicality"or disapproval by city council.What......?
Sessions used MJ in the same sentence along with Cocaine and heroine.
Great exposure.ERBB on!
Front page of USA Today.
http://usatoday.newspaperdirect.com/epaper/viewer.aspx
News out?Up 8%
I'm glad to hear that your doing your own DD.Thanks
Seesawing?From over $3 to $.70?That's a tidal wave.
Where's the new CEO?
Not an OTC problem.It seems management is the problem.
Whats going on with this stock?No updates or anything.Is this one over?
Latest Legal Medical Marijuana Legislature Approvals are a Great Sign for Continued Growth of Cannabis Industry
5 hours 23 minutes ago - DJNF
PALM BEACH, Florida, May 8, 2017 /PRNewswire/ --
The medical cannabis industry is once again taking a step forward as additional U.S. states have allowed medical marijuana and medical cannabis oil for a growing number of treatments for diseases and certain medical conditions. This is a good indication that the production of legal marijuana products in approved states could see a sudden uptick in business for companies such as: Marapharm Ventures Inc. (OTC: MRPHF) (CSE: MDM.CN), Eco Science Solutions, Inc. (OTC: ESSI), OWC Pharmaceutical Research Corp. (OTC: OWCP), Medical Marijuana, Inc. (OTC: MJNA) and Vitality Biopharma, Inc. (OTC: VBIO).
Marapharm Ventures Inc. (OTCQB: MRPHF) (CSE: MDM.CN) announces a financial update on the 2nd anniversary of trading as a public company - it has raised $22,917,150.00 - The Company was listed on the CSE and began trading on May 8, 2015, with subsequent listings on the OTCQB and the FSE. Marapharm has raised $22,917,150.00 (share source: Computer Share; Transfer Agent). The proceeds have been raised by private placements, and the exercise of options and warrants as a public company. The first tranche of the bond offering, announced on February 28, 2017 is closed, the total is USD $1,280,000.00. There is $4,220,000.00 remaining and is available for subscription. There are two warrant series left to be exercised for a potential of $4,951,200.00. Marapharm has approximately $5 million cash at the present time. Read a full list of achievements for Marapharm along with the full press release & other news at: http://marketnewsupdates.com/news/mrphf.html
"We have worked hard during the past two years, and now, Marapharm is ready to grow. We have created a strong infrastructure and shareholder base. We have licenses, property and buildings."
"Coupon and convertible bonds have been used to raise construction money. Several lenders and investors have presented financing proposals for further construction options including an $80 million dollar USD conditional commitment. We will continue to scrutinize all proposals to ensure the best decisions are made for Marapharm."
"The past 2 years have been significant. We have set a foundation for long term success and expansion in this exciting market. The next few years are going to be historical!" said Linda Sampson, Marapharm CEO. Marapharm has traded 98,923,854 million shares on three stock markets for a value of $126,564,847.00 CDN in its first two years of public trading clearances.
In other cannabis industry news and performances of note:
Eco Science Solutions, Inc. (OTCQB: ESSI), an eco-technology Company providing solutions to the multi-billion-dollar health, wellness and alternative medicine industry, this past Friday announced that it has signed a Letter of Intent with Ga-Du Bank, Inc. for the purpose of acquiring full ownership of the Bank in a stock and cash transaction. Upon the closing of the transaction, ESSI will operate the Bank as a wholly-owned subsidiary of Eco Science Solutions, Inc. ESSI will own and operate a financial banking division providing payment processing, cash management and financial services to its customers in the cannabis industry.
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), an Israeli-based research company engaged in the development of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, last week announced that the Scientific Advisory Team of its wholly-owned Israeli subsidiary, One World Cannabis Ltd. ("OWC") has determined the road map for continuing the Multiple Myeloma study. The purpose of the next phase of the study, which is based upon the promising results of the Company's earlier in-vitro studies of its unique formula of cannabinoid-based therapies targeting cells, is to investigate the doses and diverse delivery systems, [e.g. per os/oral vs. per rectum] in order to best determine the most effective dosages and means of delivery for a future planned study on human patients following receipt of regulatory approvals. The Company expects that the continued study will be completed during Q3 of this year.
Medical Marijuana, Inc. (OTC: MJNA), the first publicly traded cannabis company in the United States, announced last Friday that it has expanded its innovative product offerings to include a variety of vaporizers designed to provide consumers with a safe and enjoyable delivery method for dry herbs and concentrates. Now available to purchase on the Medical Marijuana Inc. website are tabletop (commonly referred to as 'desktop'), portable, and pen vaporizers designed for dry herb as well as concentrate consumption (use depends on model). Featured brands include Storz & Bickel, PAX, Herbalizer, Firefly, KandyPens, and Magic Flight.
Latest Legal Medical Marijuana Legislature Approvals are a Great Sign for Continued Growth of Cannabis Industry
5 hours 23 minutes ago - DJNF
PALM BEACH, Florida, May 8, 2017 /PRNewswire/ --
The medical cannabis industry is once again taking a step forward as additional U.S. states have allowed medical marijuana and medical cannabis oil for a growing number of treatments for diseases and certain medical conditions. This is a good indication that the production of legal marijuana products in approved states could see a sudden uptick in business for companies such as: Marapharm Ventures Inc. (OTC: MRPHF) (CSE: MDM.CN), Eco Science Solutions, Inc. (OTC: ESSI), OWC Pharmaceutical Research Corp. (OTC: OWCP), Medical Marijuana, Inc. (OTC: MJNA) and Vitality Biopharma, Inc. (OTC: VBIO).
Marapharm Ventures Inc. (OTCQB: MRPHF) (CSE: MDM.CN) announces a financial update on the 2nd anniversary of trading as a public company - it has raised $22,917,150.00 - The Company was listed on the CSE and began trading on May 8, 2015, with subsequent listings on the OTCQB and the FSE. Marapharm has raised $22,917,150.00 (share source: Computer Share; Transfer Agent). The proceeds have been raised by private placements, and the exercise of options and warrants as a public company. The first tranche of the bond offering, announced on February 28, 2017 is closed, the total is USD $1,280,000.00. There is $4,220,000.00 remaining and is available for subscription. There are two warrant series left to be exercised for a potential of $4,951,200.00. Marapharm has approximately $5 million cash at the present time. Read a full list of achievements for Marapharm along with the full press release & other news at: http://marketnewsupdates.com/news/mrphf.html
"We have worked hard during the past two years, and now, Marapharm is ready to grow. We have created a strong infrastructure and shareholder base. We have licenses, property and buildings."
"Coupon and convertible bonds have been used to raise construction money. Several lenders and investors have presented financing proposals for further construction options including an $80 million dollar USD conditional commitment. We will continue to scrutinize all proposals to ensure the best decisions are made for Marapharm."
"The past 2 years have been significant. We have set a foundation for long term success and expansion in this exciting market. The next few years are going to be historical!" said Linda Sampson, Marapharm CEO. Marapharm has traded 98,923,854 million shares on three stock markets for a value of $126,564,847.00 CDN in its first two years of public trading clearances.
In other cannabis industry news and performances of note:
Eco Science Solutions, Inc. (OTCQB: ESSI), an eco-technology Company providing solutions to the multi-billion-dollar health, wellness and alternative medicine industry, this past Friday announced that it has signed a Letter of Intent with Ga-Du Bank, Inc. for the purpose of acquiring full ownership of the Bank in a stock and cash transaction. Upon the closing of the transaction, ESSI will operate the Bank as a wholly-owned subsidiary of Eco Science Solutions, Inc. ESSI will own and operate a financial banking division providing payment processing, cash management and financial services to its customers in the cannabis industry.
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), an Israeli-based research company engaged in the development of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, last week announced that the Scientific Advisory Team of its wholly-owned Israeli subsidiary, One World Cannabis Ltd. ("OWC") has determined the road map for continuing the Multiple Myeloma study. The purpose of the next phase of the study, which is based upon the promising results of the Company's earlier in-vitro studies of its unique formula of cannabinoid-based therapies targeting cells, is to investigate the doses and diverse delivery systems, [e.g. per os/oral vs. per rectum] in order to best determine the most effective dosages and means of delivery for a future planned study on human patients following receipt of regulatory approvals. The Company expects that the continued study will be completed during Q3 of this year.
Medical Marijuana, Inc. (OTC: MJNA), the first publicly traded cannabis company in the United States, announced last Friday that it has expanded its innovative product offerings to include a variety of vaporizers designed to provide consumers with a safe and enjoyable delivery method for dry herbs and concentrates. Now available to purchase on the Medical Marijuana Inc. website are tabletop (commonly referred to as 'desktop'), portable, and pen vaporizers designed for dry herb as well as concentrate consumption (use depends on model). Featured brands include Storz & Bickel, PAX, Herbalizer, Firefly, KandyPens, and Magic Flight.
Thanks.It would be nice if you could hear it..
Sessions needs to burn a big fatty!
The Cannabis Science Versus Cancer and Other Malignancies and the Palliative Care and Mental Health Sessions at the Global Health Catalyst (GHC) Summit at Harvard Medical School April 28-30, 2017 will be live-streamed to an audience worldwide. Those interested in joining the live-streaming of these sessions, as well as any of the other GHC Summit sessions, can subscribe to the Next Generation Global Health Security Network YouTube Channel at https://www.youtube.com/channel/UCqihIfrETTl2eRMxNQxUCDQ. Additionally, the recorded sessions can be accessed via this YouTube channel.
Cannabis Science Selects Influential Southern California Financial Firm as the Lead to Raise the Proposed 25 Million USD in Expansion Capital and Boost its Industry Footprint
IRVINE, CA -- (Marketwired) -- 04/27/17 -- Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is pleased to announce that it has selected an influential Southern California Financial Firm as the lead to raise the proposed 25 Million USD in expansion capital and boost its industry footprint by pursuing several industry business models on behalf of the Company within the Cannabis Industry.
"We have been enthusiastically reviewing investment firms that have expressed interest in our business model that have similar humanitarian interests and dedication to the industry, and we didn't have to look far. We think we certainly found the right group, with the right mindset, and the right track record. We expect to formally announce the Firm once preparations are complete for a formal presentation directly after the Global Health Catalyst (GHC) Summit @ Harvard Medical School," stated Mr. Raymond C. Dabney, President & CEO, Co-Founder, Cannabis Science Inc.
"As a direct result of our CRA with Dana Farber we have experienced a considerable increase in the number of expanded research collaborations requests targeting several ailments from Universities, Foundations, Corporations, and Private Investors. These groups seem to have one thing in common: they are all looking to get involved with our research programs with Dana Farber and beyond. They are looking to target one or more critical ailments of interest to their group or just invest in a study based on their previous life experiences. This is exactly what we were hoping for, expansion through partnerships and acquisitions.
"We have also experienced a very large number of self-medicating patients looking for cannabinoid information or actual new cannabinoid medication they can purchase for their specific condition. This is truly profound, what is happening right now, all around us; once again we are certainly making history with all those working with us, especially Dana Farber. We are certainly blessed and our goal is to pass on our knowledge, medications, and resources to the millions of patients worldwide seeking natural alterative medications for their conditions. The anticipated 25 Million in new funding will certainly allow us to meet this demand while we fast tracking our formal FDA initiatives through Dana Farber and really begin to make a noticeable difference," stated Mr. Raymond C. Dabney, President & CEO, Co-Founder, Cannabis Science Inc.
About the Global Health Catalyst (GHC) Summit @ Harvard Medical School, April 28-30, 2017
The Cannabis Science Versus Cancer and Other Malignancies and the Palliative Care and Mental Health Sessions at the Global Health Catalyst (GHC) Summit at Harvard Medical School April 28-30, 2017 will be live-streamed to an audience worldwide. Those interested in joining the live-streaming of these sessions, as well as any of the other GHC Summit sessions, can subscribe to the Next Generation Global Health Security Network YouTube Channel at https://www.youtube.com/channel/UCqihIfrETTl2eRMxNQxUCDQ. Additionally, the recorded sessions can be accessed via this YouTube channel.
Mr. Dabney and Dr. Herman will be the keynote speakers and panelists for the Cannabis Science Versus Cancer and Other Malignancies Session. The theme for this session is "Medical Cannabis in Global Health," and speakers and panelists will provide updates on leading-edge collaborations investigating the use of medical cannabis in the treatment of cancer and other malignancies, and closing the global pain divide.
Information on this session is available at:
https://www.globalhealthcatalystsummit.org/medical-cannabis
Information on the GHC Summit is available at:
http://www.globalhealthcatalystsummit.org
About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Cannabis Science, Inc.
Dr. Allen Herman
Chief Medical Officer (CMO)
allen.herman@cannabisscience.com
Tel: 1-888-263-0832
Cannabis Science, Inc.
Mr. Raymond C. Dabney
President & CEO, Co-Founder
raymond.dabney@cannabisscience.com
Tel: 1-888-263-0832
Cannabis Science, Inc.
Investor Relations
Teresa Misenheimer
Email: teresa@cannabisscience.com
Tel: 1-888-263-0832
CBIS selects financial firm to raise $25 million.
Shorts covering?
Chart looks primed for an upswing.Reversal may be happening.Let's hope so.
Just what CBIS needs.A PR stating that a stock worth 7/10000th of a penny has better ratings than an 7 cent stock.
Just what MJNA needs.A PR stating that a stock worth 7/10000th of a penny has better ratings than an 12 cent stock.
Sorry,it looks like that is the Canadian ETF.When will Agrosphere ETF start?
I thought the ETF started trading on April 5th.
Thanks!
Link to news?
Raymond Dabney to speak at Harvard:
Session 3: Medical Cannabis Science vs Cancer & other malignancies
(Chairs, Allen Herman, Donna Christensen)
2:00 pm Featured speakers:
Raymond Dabney (Founder and CEO, Cannabis Science Inc)
Allen Herman (Chief Medical Officer, CBIS)
Roscoe M. Moore Jr (Former U.S. Assistant Surgeon General, Chair of the Constituency for Africa)
Congresswoman Donna Christensen
Other speakers
Good bye Hangout/ Tour of Harvard MIT facilities
Will this ever get back to .10?
It all depends .MACD will cross at different times depending on the time frame.On the 1 year daily chart it looks like it's about to cross over.
I sure would like to see that list!
I think a sell order and a stop order are the same thing.
Comprehensive highlights from the 10K.
Risks Related to Our Financial Position and Capital Requirements
Our independent registered public accounting firm has expressed substantial doubt as to our ability to continue as a going concern.
We face many of the risks and difficulties frequently encountered by relatively new companies with respect to our operations.
Risks Relating to Our Product Prospects and Future Products, Our Services and the Cannabis Industry
Changes in consumer preferences and acceptance of cannabis-based medical products and treatments and any negative trends will adversely affect our business.
Our involvement in the cannabis industry may make it difficult to obtain insurance coverage.
We are entering a potentially highly competitive market.
Changes in legislation or regulation in the health care systems in the United States and foreign jurisdictions may affect us.
We depend substantially on collaboration with our research and development partners.
Collaboration agreements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize cannabis-based medical products.
Our failure to comply with existing and potential future laws and regulations relating to drug development could harm our plan of operations.
The FDA has not approved the whole-plant extract of Cannabis as a safe and effective drug for any indication.
Failure to secure the necessary Israeli licenses to use cannabis for medical research could limit our ability to execute our research and development activities, delay the launch of our products and adversely affect the results of our business operations.
If we choose to distribute our future products in the United States, we will be subject to controlled substance laws and regulations; failure to receive necessary approvals may delay the launch of our products and failure to comply with these laws and regulations may adversely affect the results of our business operations.
Our ability to provide consulting services in the United States is dependent on additional states legalizing medical marijuana.
State and municipal governments in which we provide consulting services or seek to provide consulting services may have, or may adopt laws that adversely affect our ability to do business.
The businesses for which we plan to provide consulting services may have difficulty accessing the services of banks in the United States, which may make it difficult for them to purchase our products and services.
If we choose to engage in research and development or consulting activities in Europe, controlled substance legislation may restrict or limit our ability to provide consulting services or to research, manufacture and develop a commercial market for our products.
Laws and regulations affecting therapeutic uses of marijuana are constantly evolving.
Risks Related to Intellectual Property
Costly litigation may be necessary to protect our intellectual property rights and we may be subject to claims alleging the violation of the intellectual property rights of others.
If we are unable to protect our intellectual property adequately, our business and commercial prospects will suffer.
Risks Related to Management and Personnel
If we are unable to hire and retain key personnel, we may not be able to implement our business plan and our business may fail.
Risks Related to Our Common Stock
There can be no assurance of a liquid public trading market for our common stock or whether investors will be able to readily be able to sell their shares of common stock.
In the event an active trading market develops for our common stock, the market price may, from time-to-time, be volatile.
A large number of additional shares will be available for resale into the public market pursuant to Rule 144, which may cause the market price of our common stock to decline significantly.
You will experience dilution of your ownership interest because of the future issuance of additional shares of our common stock or our pre
Insiders will continue to have substantial control over us after this offering and will be able to influence corporate matters.
We may never pay any dividends to our shareholders.
Anti-takeover provisions of the Delaware General Corporation Law may discourage or prevent a change of control, even if an acquisition would be beneficial to our shareholders, which could reduce our stock price.
State Blue Sky registration and potential limitations on resale of our common stock.
Our common stock is considered a Penny Stock, which may be subject to restrictions on marketability, so you may not be able to sell your shares.
The material weaknesses in our internal control over financial reporting may until remedied cause errors in our financial state
Our shares of common stock are thinly traded, so stockholders may be unable to sell at or near ask prices or at all if they need to sell shares to raise money or otherwise desire to liquidate their shares.
Reporting requirements under the Exchange Act and compliance with the Sarbanes-Oxley Act of 2002, including establishing and maintaining acceptable internal controls over financial reporting, are costly and may increase substantially.
Our by-laws provide for indemnification of our directors and the purchase of D&O insurance at our expense and limit their potential or actual liability which may result in a significant cost to us and damage the interests of our shareholders.
Upon dissolution of the Company, our stockholders may not recoup all or any portion of their investment.
Why is there a new interim CEO for OWC?Didn't this stock just recently push past $3?
Scottrade won't allow stop orders on OTC stocks.
Does anyone else notice their FITX account fluctuating on a daily basis?Sometimes up or down 100's of dollars.Why is this happening?FITX Quit using my shares for other endeavors.
I agree.Only the top performing MJ stocks should be admitted and the entry into the ETF should be conditional.